CRC Research Update — September 05, 2026
Today's colorectal cancer research highlights
mrd
A collection of 26 issues
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
Skip to content
The CRC Digest
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
A prospective study of 1,000 stage II-III CRC patients found that distinct perioperative immunocircadian recovery trajectories were associated with postoperative ctDNA-based minimal residual disease and long-term survival outcomes. (Surgery)
This content is informational
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
A review examines how circulating tumor DNA (ctDNA) offers a dynamic readout of molecular residual disease in the postoperative period, potentially guiding adjuvant treatment decision-making in stage II (15-20% recurrence) and
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
Skip to content
The CRC Digest
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer
CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 22, 2026
Today's colorectal cancer research highlights
New ctDNA assay validated for minimal residual disease monitoring across solid tumors
Skip to content
The CRC Digest
◇ RESEARCH
New ctDNA assay validated for minimal residual disease monitoring across solid tumors
The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low
CRC Research Update — August 10, 2026
Today's colorectal cancer research highlights
Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease
Skip to content
The CRC Digest
▪ RESEARCH
Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease
A translational science review in JAMA reports that circulating tumor DNA (ctDNA) sequencing can identify gene variants to inform treatment selection in colorectal cancer, and that detecting ctDNA after curative intent therapy correlates
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
Skip to content
The CRC Digest
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant